Source comparison
IPAM vs Ipamorelin: Molecular Structure and Receptor Targets
IPAM (sometimes referenced as CJC-1293 or Hexarelin analogue in older literature) is a synthetic peptide designed to mimic endogenous insulin-potentiating factors. Its primary mechanism involves binding to insulin receptor substrate-1 (IRS-1) and enhancing GLU
This comparison does not assign a generated winner or score.
- IPAM (sometimes referenced as CJC-1293 or Hexarelin analogue in older literature) is a synthetic peptide designed to mimic endogenous insulin-potentiating factors. Its primary mechanism involves binding to insulin receptor substrate-1 (IRS-1) and enhancing GLUT4 glucose transporter expression in skeletal muscle cells. Effectively amplifying insulin-mediated glucose uptake without increasing circulating insulin levels. The peptide's amino acid sequence contains specific binding domains that interact with PI3K/Akt signalling pathways, which regulate cellular glucose metabolism independent of pancreatic beta-cell activity.
- Ipamorelin, by contrast, is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that functions as a selective ghrelin receptor agonist. It binds to growth hormone secretagogue receptor 1a (GHS-R1a) on somatotroph cells in the anterior pituitary, triggering calcium influx and subsequent growth hormone release. Unlike GHRP-2 or GHRP-6, Ipamorelin demonstrates high selectivity for GH release. Studies show minimal to no increase in cortisol or prolactin at standard research doses (200–300 mcg in animal models). The peptide's half-life is approximately two hours, requiring multiple daily administrations to maintain elevated GH levels in experimental protocols.
- The structural difference is fundamental: IPAM contains 28–32 amino acids depending on the analogue variant, while Ipamorelin is a 5-residue peptide. This size disparity alone dictates different pharmacokinetic profiles. IPAM's larger structure allows for slower renal clearance and extended plasma stability, while Ipamorelin's compact sequence is rapidly metabolised by peptidases.